Order 1218n on radiopharmaceutical preparation in Russian clinics is valid until 1 January 2027. What clinics should do now
Radiopharmaceutical medicinal products (hereinafter radiopharmaceuticals) prepared directly in medical organizations under the procedure established by the authorized federal executive body are not subject to state registration (under the Federal Law on the Circulation of Medicines, 61-FZ). For all other radiopharmaceuticals the general rule applies: the manufacture, storage, transportation, import into Russia, export from Russia, advertising, dispensing, sale, transfer and use of medicinal products are permitted if they are registered (under 61-FZ).
A manufacturer releases radiopharmaceuticals under the Good Manufacturing Practice rules of the Eurasian Economic Union (EAEU GMP) and holds a manufacturing license (under 61-FZ). A medical organization prepares radiopharmaceuticals under the procedure that the Russian Ministry of Health approved by Order of 12 November 2020 No. 1218n. The period of validity of this order ends on 1 January 2027.
What regimes exist and how to tell them apart
Two regimes apply to radiopharmaceuticals: industrial manufacturing and preparation directly in a medical organization. A radiopharmaceutical contains, in its ready-to-use state, one or more radionuclides (radioactive isotopes) as the active substance or as part of it (under the Rules for Registration and Regulatory Review of Medicines for Medical Use approved by Decision of the EEC Council of 3 November 2016 No. 78, hereinafter the Registration Rules). The law calls such products radiopharmaceutical medicines, while the Procedure for the Preparation of Radiopharmaceutical Medicinal Products Directly in Medical Organizations, approved by Order of the Russian Ministry of Health of 12 November 2020 No. 1218n (hereinafter Order No. 1218n), and the Registration Rules call them radiopharmaceutical medicinal products.
The law applies to the circulation of radiopharmaceutical medicines with the specifics established by legislation in the field of radiation safety. This legislation includes Federal Law of 9 January 1996 No. 3-FZ «On Radiation Safety of the Population» (hereinafter 3-FZ). When handling sources of ionizing radiation, organizations are required to carry out production control of the radiation situation, to monitor and record the individual radiation doses of workers, to train and certify workers in radiation safety, and to arrange their preliminary and periodic medical examinations. A radiation hazard sign is applied to the primary and secondary packaging of radiopharmaceutical medicines (under 61-FZ).
Order No. 1218n regulates preparation directly in medical organizations. It does not apply to the manufacture of radiopharmaceuticals and does not regulate the use of radiopharmaceuticals that are already registered. Radiopharmaceuticals prepared directly in medical organizations under the procedure established by the authorized bodies of the member states are excluded from registration under the Union rules (under the Registration Rules).
The Good Manufacturing Practice Rules of the Eurasian Economic Union, approved by Decision of the EEC Council of 3 November 2016 No. 77 (hereinafter the EAEU GMP Rules), contain special requirements for the manufacture and quality control of radiopharmaceuticals, radiopharmaceuticals for positron emission tomography (PET), radiopharmaceutical precursors and radionuclide generators in industrial production facilities, nuclear centers, institutes and PET centers (hereinafter the special requirements for radiopharmaceuticals). These requirements do not apply to the preparation of radiopharmaceuticals in specialized pharmacies (hospital pharmacies or independent ones) using radionuclide generators and reagent kits in accordance with the legislation of the member states. They also apply to radiopharmaceuticals used in clinical trials, and their manufacture is also subject to the requirements of the EAEU GMP Rules for investigational medicinal products.
Order No. 1218n lists quality indicators for radiopharmaceuticals prepared in PET centers based on cyclotrons that are located directly in medical organizations. PET centers are named in both acts: in the special requirements for radiopharmaceuticals among manufacturers, and in Order No. 1218n among the subdivisions of medical organizations. Neither act contains a criterion by which a particular PET center falls under one regime or the other, and Order No. 1218n contains no provision on the transfer of a prepared radiopharmaceutical to another medical organization.
How industrial manufacturing works
Medicines for medical use are manufactured by companies that hold a license for the manufacture of medicines (under 61-FZ). Special requirements for radiopharmaceuticals are added to the general requirements of the EAEU GMP Rules, and for the manufacturer of radiopharmaceuticals the law establishes the following:
compliance with EAEU GMP is confirmed during licensing, and as a result the manufacturer receives an EAEU GMP compliance certificate;
for licensing and for inspection of compliance with these rules, the authority that registers medicinal products transfers to the licensing control authority, on request, information on the manufacturer’s substances and products, including the manufacturing technology and the quality control methods;
the industrial regulation (promyshlenny reglament) is approved by the head of the manufacturer.
A product released by the manufacturer is put into circulation after registration (under 61-FZ) under the Registration Rules, which apply to products intended for the common market of the Union or for the territory of one member state. Before each batch or lot of a medicinal product manufactured in Russia, other than an immunobiological product, is put into civil circulation, the manufacturer submits electronically to the federal executive authority that exercises control and supervision in healthcare a manufacturer’s document confirming the quality of the product and a confirmation from the manufacturer’s Qualified Person (QP) that the product complies with the requirements established at its registration (under 61-FZ). Manufacturers do not apply means of identification (labeling for the system of monitoring the movement of medicinal products) to the packaging of radiopharmaceuticals.
Radiopharmaceuticals are manufactured in controlled areas in which the requirements for the production environment and for radiation safety are met, in premises and on equipment designated specifically for radiopharmaceuticals.
For manufacture, the special requirements for radiopharmaceuticals additionally establish the following:
where possible, closed or isolated equipment is used;
recirculation of air from rooms where radiopharmaceuticals are handled is not permitted, except where it is justified;
negative pressure relative to the surrounding areas is maintained in zones with open product;
different radiopharmaceuticals cannot be manufactured at the same time in one work zone, that is, in one hot cell, laminar zone or cabinet;
in closed automated systems for sterile radiopharmaceuticals (as a rule, hot cells with units for chemical synthesis, purification and in-line sterilizing filtration) it is sufficient to ensure cleanliness grade C, while aseptic operations are carried out in a room or zone of grade A.
The special requirements for radiopharmaceuticals refer to the requirements of the EAEU GMP Rules for the manufacture of sterile products, both for aseptic conditions of manufacture and for the cleanliness of work areas. Decision of the EEC Council of 20 May 2026 No. 67 (hereinafter Decision No. 67) restates these requirements in a new edition.
The dates of entry into force are as follows:
the main part of the new edition enters into force once 180 calendar days have passed from the date of official publication of the Decision, that is, on 28 December 2026;
the requirements on the transfer of materials into zones of grades A and B and on airlocks, on integrity testing of sterilizing and gas filters, on environmental monitoring in blow-fill-seal technology, on lyophilizer integrity and on the assessment of extractables and leachables in single-use systems enter into force once 1,095 calendar days have passed from the date of official publication of the Decision, that is, approximately on 30 June 2029.
Two provisions of the new edition concern radiopharmaceutical products. Isolators (closed chambers that separate a grade A zone from the surrounding room) with negative pressure are used only when containment of the product is important, for example for a radiopharmaceutical, and specialized risk control measures are then carried out to exclude a threat to the critical zone. The radiation hazard risk from radiopharmaceutical products is taken into account when an environmental monitoring system is selected.
Manufacturing personnel receive special training in radiation safety and instruction in the specifics of the quality assurance system for radiopharmaceuticals, and workers who are present in manufacturing areas, including cleaning and maintenance staff, receive additional training. Full responsibility for the release of radiopharmaceuticals rests with the QP, who may be a certified employee of the manufacturer with at least five years of experience in the manufacture or quality control of medicines and a higher education in one of the specialties listed in the law, including «radiation, chemical and biological protection» and «pharmacy».
The short shelf life of some radionuclides makes it possible to release and use radiopharmaceuticals on the basis of an assessment of the batch documentation before all chemical and microbiological tests are completed, provided that a special procedure clearly defines how release authorization is issued, including the responsibility of personnel and the continuous assessment of the effectiveness of the quality assurance system. Release authorization is issued in two or more stages, before and after the full analytical control is completed:
at the first stage, the designated person assesses the batch manufacturing records, including the manufacturing conditions and the analytical control carried out up to the point when transport of the radiopharmaceutical in «quarantine» status to the clinical unit is permitted (the special requirements for radiopharmaceuticals do not clarify whether the designated person is the same as the QP);
at the second stage, the QP issues the authorization after assessing the final control results and all deviations from the normal process, which are documented, justified and approved; if some results cannot be obtained before the product is used, the authorization is issued conditionally before use and finally once all results are received.
Radiopharmaceuticals with radionuclides that have a long half-life are checked for compliance with all requirements before release authorization is issued. Products that do not meet the requirements are rejected; reprocessing of material, where it is provided for, is carried out under a procedure approved in advance, while returned products are not reprocessed and are handled as radioactive waste, the handling of which the special requirements for radiopharmaceuticals do not define.
Documents on the manufacture of radiopharmaceuticals are prepared, agreed, approved and issued under a procedure set out in a written document.
The retention periods are as follows:
records are kept for at least three years, unless the legislation of the member state sets otherwise;
samples of each batch of bulk radiopharmaceuticals are kept for at least six months after the expiry of the shelf life of the finished product, unless risk management indicates otherwise;
samples of starting materials, other than solvents, gases and water, are kept for at least two years after the release of the product, and this period may be shortened if the specification for the starting material gives a shorter stability period.
By agreement with the authorized body, a different procedure for sampling and keeping samples of starting materials, materials and products manufactured to individual order or in small quantities may be set, or where keeping them may cause particular difficulties.
How preparation in a medical organization works
A medical organization prepares radiopharmaceuticals in its structural subdivision, in controlled areas (premises) that meet the sanitary rules and hygiene standards in the field of radiation safety. Order No. 1218n applies to radiopharmaceuticals for diagnostic or therapeutic use, including for PET, that are obtained using radionuclide generators, cyclotrons, reagent kits, radionuclide solutions and radiopharmaceutical precursors.
A medical organization needs two licenses to prepare radiopharmaceuticals:
a license for pharmaceutical activity that includes the work «preparation of radiopharmaceutical medicinal products for medical use» (under the Regulation on Licensing of Pharmaceutical Activity approved by Resolution of the Government of the Russian Federation of 31 March 2022 No. 547, hereinafter the Licensing Regulation);
a license for medical activity (under the Licensing Regulation).
The licensee must comply with the procedure for the preparation of radiopharmaceuticals and must involve in preparation workers with a higher or secondary pharmaceutical or medical education and additional professional education in radiochemistry and radiation safety (under the Licensing Regulation). Licenses are issued by the executive authorities of the constituent entities of the Russian Federation, and the Federal Service for Surveillance in Healthcare (Roszdravnadzor) assesses compliance with licensing requirements in federal state control (supervision) in the sphere of circulation of medicines. This control also covers radiopharmaceuticals prepared directly in medical organizations (under Order No. 1218n).
All operations for preparation and quality control are carried out in premises and on equipment designated specifically for radiopharmaceuticals. As in industrial manufacturing, different radiopharmaceuticals cannot be prepared at the same time in one work zone (a hot cell, laminar zone or cabinet), and the medical organization takes measures against cross-contamination and protects the preparation zone from radioactive contamination. Radiopharmaceuticals for parenteral administration are prepared in compliance with the pharmacopoeial requirements for sterility and, where appropriate, under aseptic conditions, and when they are filled under aseptic conditions the integrity of membrane filters is monitored. Order No. 1218n does not name cleanliness grades for premises.
All workers who are present in the preparation zones, including technical and maintenance staff and workers who do the cleaning, receive training. The document confirming that a radiopharmaceutical was prepared in accordance with the approved documentation is signed by the worker responsible for preparation, and this worker is responsible for the quality of the prepared product together with the head of the medical organization.
Preparation begins with a written request from a worker of the medical organization based on the prescription of the attending physician entered in the patient’s medical records, and each batch is checked against the quality indicators set in the specification of the medical organization.
Order No. 1218n recommends six indicators for radiopharmaceuticals made with generators and reagent kits (description, activity or volumetric activity, pH, radiochemical purity, sterility, labeling). For radiopharmaceuticals from cyclotron-based PET centers it recommends thirteen indicators, among them identity by radionuclide and by chemical structure, radionuclide purity, chemical impurities, osmolarity, residual organic solvents and bacterial endotoxins. Before dispensing, a worker of the medical organization checks the packaging, the details of the request and the labeling, and if they do not conform the product is not dispensed. The medical organization itself sets the permissible limits of changes in the characteristics of radiopharmaceuticals, including the requirements for release and shelf life. Order No. 1218n does not describe the procedure for authorizing dispensing before all control results are received.
The medical organization itself approves the system of documentation for preparation and quality assurance and keeps the radiopharmaceutical preparation log, which may be kept in electronic form (a recommended sample is given in Order No. 1218n), as well as records on the use, cleaning, disinfection and maintenance of the main equipment, which are signed by the worker who did the work and show the date and time. Order No. 1218n does not set a retention period for records, and the medical organization describes the sampling procedure itself.
The labeling of prepared radiopharmaceuticals conforms to the general pharmacopoeial monograph «Radiopharmaceutical Medicinal Products», OFS.1.11.0001.15. Such radiopharmaceuticals are stored in a closed area with restricted access and are transported in accordance with the radiation safety requirements.
Comparison of the regimes by the same parameters
| Parameter | Industrial manufacturing | Preparation in a medical organization |
|---|---|---|
| Basis and license | Manufacturing license, EAEU GMP and the special requirements for radiopharmaceuticals (61-FZ, EAEU GMP Rules) | License for pharmaceutical activity (the work «preparation of radiopharmaceuticals») and for medical activity; preparation under Order No. 1218n (Licensing Regulation) |
| Registration | Required (61-FZ) | Not required (61-FZ, Registration Rules) |
| Premises and equipment | Controlled areas, grade C is sufficient for closed systems, aseptic operations in grade A (EAEU GMP Rules) | Controlled areas under radiation safety standards, cleanliness grades not named (Order No. 1218n) |
| Personnel | QP, full responsibility for release (EAEU GMP Rules, 61-FZ) | The worker responsible for preparation and the head are responsible for quality (Order No. 1218n) |
| Quality control and batch release | Two-stage release authorization, conditional release by the QP (EAEU GMP Rules) | Check of the batch against the specification of the medical organization and control at dispensing (Order No. 1218n) |
| Documents and samples | Records for at least three years, samples of batches and starting materials (EAEU GMP Rules) | Preparation log and documentation of the medical organization, record retention period not set (Order No. 1218n) |
| Supervision | Licensing with confirmation of EAEU GMP compliance, transfer of information on products for licensing and inspection, documents on each batch to the healthcare control and supervision authority (61-FZ) | Federal state control (supervision) (Order No. 1218n) |
What will happen to Order No. 1218n after 1 January 2027
The law and the Licensing Regulation refer to the procedure for the preparation of radiopharmaceuticals that the authorized body establishes, and they do not name Order No. 1218n by number. Order No. 1218n is valid until 1 January 2027. There are no provisions on the preparation of radiopharmaceuticals in medical organizations for the period after that date in 61-FZ, in the Licensing Regulation or in Order No. 1218n. A replacing or extending order has not been identified in open sources as of 16 October 2026.
What to do
Determine the regime by the place of preparation. The product is prepared directly in your medical organization (Order No. 1218n, registration is not needed) or is supplied by a manufacturer (registration and EAEU GMP). The boundary is set by Order No. 1218n and by 61-FZ.
Check licenses and worker qualifications before preparation begins. A license for pharmaceutical activity that includes the work «preparation of radiopharmaceuticals» and a license for medical activity are needed, and the workers need a higher or secondary pharmaceutical or medical education and additional professional education in radiochemistry and radiation safety (under the Licensing Regulation).
Check the documentation of the medical organization against Order No. 1218n. Check the specifications for each radiopharmaceutical, the procedures for cleaning and maintaining equipment, the preparation log, the procedure for requests and control at dispensing. GOST R 57298-2024 contains recommendations for the preparation of radiopharmaceuticals in small quantities; the mandatory requirements are set by other acts.
Request from the manufacturer information on registration and on the GMP certificate. A supplied radiopharmaceutical needs a registration certificate and an EAEU GMP compliance certificate (under 61-FZ).
Until 1 January 2027, follow the order of the Russian Ministry of Health that will replace or extend Order No. 1218n. If there is no such order, send the Russian Ministry of Health a written question on the procedure for preparing radiopharmaceuticals after that date.
A radiopharmaceutical prepared in a medical organization is not registered and is prepared under Order No. 1218n. A manufacturer’s radiopharmaceutical is registered and is manufactured under EAEU GMP if a compliance certificate is held, and each batch is released by the QP. Order No. 1218n is valid until 1 January 2027, and as of 16 October 2026 there is no act on the procedure for preparation for the next period.
Regulatory framework:
1. Federal Law of 12 April 2010 No. 61-FZ «On the Circulation of Medicines» (version of 4 August 2026)
2. Decision of the EEC Council of 3 November 2016 No. 77 «On Approval of the Good Manufacturing Practice Rules of the Eurasian Economic Union» (version of 4 July 2023)
3. Decision of the EEC Council of 20 May 2026 No. 67 «On Amendments to the Good Manufacturing Practice Rules of the Eurasian Economic Union»
4. Federal Law of 9 January 1996 No. 3-FZ «On Radiation Safety of the Population» (version of 31 July 2025)
5. Decision of the EEC Council of 3 November 2016 No. 78 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (version of 26 November 2025)
6. Order of the Russian Ministry of Health of 12 November 2020 No. 1218n «On Approval of the Procedure for the Preparation of Radiopharmaceutical Medicinal Products Directly in Medical Organizations»
7. Resolution of the Government of the Russian Federation of 31 March 2022 No. 547 «On Approval of the Regulation on Licensing of Pharmaceutical Activity» (version of 27 March 2026)
8. GOST R 57298-2024 «Radiopharmaceutical Medicinal Products. General Rules for Production and Preparation» (approved by Order of Rosstandart of 10 July 2024 No. 910-st, in force from 1 March 2025)